A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats

Sung-A Chang,1,2 Byung-Kwan Lim,*1
You Jung Lee,1 Mi-Kyung Hong,2 Jin-Oh Choi,1,3 and Eun-Seok Jeon1,2

1Division of Cardiology, Department of Medicine, and 2Cardiovascular Imaging Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 3Department of Biomedical Science, Jungwon University, Goesan-gun, Korea

*Sung-A Chang and Byung-Kwan Lim contributed equally to this study.

Received: 16 June 2014
Accepted: 13 February 2015

Address for Correspondence:
Eun-Seok Jeon, MD
Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Iweon-ro, Gangnam-gu, Seoul 135-710, Korea
Tel: +82.2-3410-3448, Fax: +82.2-3410-3849
E-mail: eunseok.jeon@samsung.com

Funding: This study was supported by an investigator initiative research grant from Boryung Pharmaceutical, Inc., and by grants (Jeon ES, Lee YS) from the Korea Samsung Biomedical Research Institute (SBRI GL1-B2-271-1) (Jeon ES, Lim BK).

INTRODUCTION

Doxorubicin (DOX) is the most commonly used chemotherapeutic agent and is frequently included in chemotherapy regimens for the treatment of lung, breast, stomach, ovarian, thyroid cancer, soft tissue sarcoma multiple myeloma and some leukemias and Hodgkin’s lymphoma.

The acute adverse effects of DOX, such as nausea, vomiting, alopecia, and neutropenia, are usually nonfatal or reversible. However, cardiotoxicity is the most serious sequelae of DOX-based chemotherapy (1).

Cardiotoxicity is associated with cumulative doses of DOX. An empirical dose limit of 500 mg per m² is recommended as the cut-off value to minimize DOX-induced cardiotoxicity (2). Several clinical risk factors have been implicated in DOX-induced cardiomyopathy (3, 4). However, even in patients without any risk factors, development of DOX-induced cardiotoxicity has been reported (1). Therefore, monitoring cumulative doses of DOX may fail to prevent cardiac toxicity, which can occur unexpectedly. The mortality and morbidity of DOX-induced dilated cardiomyopathy are high and often irreversible; therefore, preventive management and cautious monitoring are needed during the chemotherapy. Even with the cardiac risks associated with DOX, it is still included in many chemotherapy regimens because of its efficacy in various cancers.

Preventive management of DOX-induced cardiomyopathy mainly includes close monitoring during treatment and early termination when cardiotoxicity is suspected (5); however, deterioration is often observed even after termination of chemotherapy. Experimental and human data suggest that anti-oxidative treatment or angiotensin-converting enzyme/angiotensin-receptor antagonists may have protective effects. In this study, we investigated whether pretreatment with two different doses of a new angiotensin-receptor antagonist, fimasartan, could prevent DOX-induced cardiotoxicity and improve survival rates.

MATERIALS AND METHODS

Study design
The protocols used in this study conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication 85-23, revised 1996). A total of 71 eight-week-old Sprague-Dawley rats weighing 250-300 g was used (Fig. 1). Echocardiography was performed in all ani-
Echocardiography and non-invasive blood pressure (NIBP) measurements were performed in all the study animals at weeks six and eight from baseline, and hemodynamic evaluation was performed at week nine from baseline.

**Echocardiography**

Echocardiography was performed at baseline, six weeks, and eight weeks. The rats were anesthetized by the 1.5% isoflurane inhalation method with nosecone. Images were acquired with a 12 MHz linear transducer connected to a Vivid-7 echocardiography machine (GE Medical, Milwaukee, WI, USA). M-mode and two-dimensional echocardiography images were acquired at the papillary muscle level with a frame rate of 80-120/sec. LV end-diastolic septal and posterior wall thickness (SWT and PWT), LV end-diastolic dimension (LVEDD), and LV end-systolic dimension (LVESD) were measured. The LV ejection fraction (LVEF) was calculated according to the following formula: LVEF = (LVEDD³ - LVESD³)/LVEDD³. A single echocardiographer who was blinded to the treatment information performed all echocardiograms for data acquisition.

**Hemodynamic measurements**

One week after echocardiography (week nine after treatment), rats were intubated with a 16-gauge catheter after induction of anesthesia with 5% isoflurane. Anesthesia was maintained with 1.5% isoflurane and the animals were placed in the recumbent position on a heat pad with a rectal probe connected to a thermodilution catheter. The animals were then intubated with a blunt 16-gauge needle using the tracheotomy method and ventilated with a custom-designed constant-pressure ventilator at 75 breaths/min using room air. An anterior thoracotomy was performed and a small apical stab was made to expose the LV apex. Electrocautery was used to minimize bleeding during the surgical procedure.

After the apex of the LV was stabilized with a 27-gauge needle, a micro tip pressure-volume (P-V) catheter (SPR-838, Millar Instruments; Houston, TX, USA) was inserted retrograde into the LV cavity along the cardiac longitudinal axis until stable P-V loops were obtained (6). Polyethylene catheters (PE-50) were inserted into the right femoral artery for measurement of mean arterial pressure. The right internal jugular vein was used as a central venous line for fluid administration. The abdominal wall was opened, and the inferior vena cava (IVC) and portal vein were exposed. A snare suture was placed to modulate rapid IVC obstruction. All loops were acquired after 20 min of stabilization with the ventilator turned off for 5-10 sec. The sampling rate was 1,000/s using the ARIA P-V conductance system (Millar Instruments) coupled to a PowerLab 16/30 A/D converter (AD Instruments; Mountain View, CA, USA) and a personal computer. After the data were recorded under steady state and preload reduction by IVC ligation, parallel conductance (Vp) was measured.

stress imposed on the animals. Body weight was measured every week from baseline through week nine. The general condition and mortality of rats were monitored daily and a survival curve was derived.
obtained by injecting 500 µL of 15% hypertonic saline into the central venous line.

Volume calibration was performed using the electrical cuvette method. Electrical cuvettes (Millar Instruments) were filled with 500 µL of fresh blood and blood viscosity was determined. After acquisition of Vc, at the end of hemodynamic evaluation, volume correction with Vb was performed and loops were analyzed using a commercially available cardiac P-V analysis program, PVAN Ultra V1.0.2 (Millar Instruments). Heart rate, LV end-diastolic pressure (EDP), maximal slope of systolic pressure increment (+dP/dt) and diastolic pressure decrement (-dP/dt), LVEF; end-systolic and end-diastolic volume (ESV and EDV), and stroke volume were calculated.

LV P-V relations were measured via transient occlusion of the IVC with a silk snare suture. Successive cardiac cycles (10-20) were obtained over 5 sec, from which the end-systolic pressure volume relation (ESPVR) slope, SW-EDV relation (preload recruitable stroke work [PRSW]), slope of the maximum first derivative of ventricular pressure with respect to time (dP/dtmax)-EDV relation, and end-diastolic pressure volume relation (EDPVR) slope were derived.

**Western blot analysis**

For Western blot analysis, heart was lysed in RIPA buffer (50 mM Tris [pH 8.0], 0.1% SDS, 1% NP40, 150 mM NaCl, 0.5% sodium-deoxycholate). Aliquots of total heart extract (10 µg) were loaded onto 12% SDS-PAGE gels, electrophoresed for 4 hr at 100 V, and then transferred to Hybond-ECL nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, USA). The membranes were blocked in 5% non-fat dry milk solution in phosphate-buffered saline (PBS) containing 0.1% Tween 20 and then probed with commercial antibodies to phospho-ERK (extracellular signal-regulated kinase), total ERK, phospho-AKT, and total AKT with the appropriate secondary antibodies. After incubation in ECL solution, membranes were exposed to x-ray film.

**Statistical analysis**

Data were reported as means and standard deviations. One way analysis of variance (ANOVA) with post-hoc analysis or Kruskal-Wallis test was used to compare mean values of the groups where appropriate. Kaplan-Meier survival curves were constructed and log-rank tests were performed. A value of \( P < 0.05 \) was considered statistically significant. Statistical analysis was performed with IBM SPSS Statistics (Version 19.0, IBM SPSS Inc., Chicago, IL, USA).

**ETHICS STATEMENT**

All procedures were reviewed and approved by the institutional animal care and use committee of Samsung Biomedical Research Institute (SBRI) [IRB No. S-B1-005]. SBRI is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International and abides by the Institute of Laboratory Animal Resources guide.

**RESULTS**

There were no differences among the groups in baseline characteristics, including blood pressure or echocardiographic findings (Table 1). Mean blood pressure in the High-fima group was significantly decreased at eight weeks (80.8 ± 7.3 mmHg) compared to the NC group (108.0 ± 9.2 mmHg, \( P = 0.01 \)) and the DOX-only group (97.0 ± 6.9 mmHg, \( P = 0.001 \), Fig. 2A). Body weight increased until week three from baseline, and then decreased from weeks four to nine in all DOX-only animals (Fig. 2B). In contrast, rats in the NC group showed gradually increasing body weight until the end of the study. At eight weeks, body weights in both fimasartan-treated groups (Low-fima 320.3 ± 40.7 g, High-fima 317.2 ± 34.0 g) were higher than those in the DOX-only group (279.3 ± 50.4 g, Fig. 2B).

Echocardiographic data showed progressive LV systolic dysfunction and dilation of the LV cavity in the DOX-only group (Fig. 2C and D, Table 2). Specifically, LVESD at six weeks was maintained until end of the study in both the High-fima (4.94 ± 1.08 mm vs. 3.60 ± 0.55 mm, \( P = 0.007 \)) and NC groups (4.93 ± 0.68 mm vs. 3.67 ± 0.46 mm, \( P = 0.017 \)), whereas in the DOX-only group, LVESD rapidly increased from four weeks (9.69 ± 1.11 mm, Fig. 2C) to eight weeks (14.77 ± 1.06 mm, \( P = 0.007 \))

| Table 1. Baseline characteristics of study animals |
|-----------------------------------------------|
| Parameters | Doxorubicin group | Normal control |
|-----------|------------------|----------------|
|           | Dox-only (n = 22) | Low-fima (n = 22) | High-fima (n = 19) | Normal control (n = 8) |
| Body weight (g) | 310.7 ± 29.3 | 310.3 ± 30.3 | 308.6 ± 29.7 | 300.1 ± 25.4 |
| Systolic BP (mmHg)* | 103.8 ± 7.7 | 100.7 ± 8.9 | 98.9 ± 7.0 | 97.6 ± 7.4 |
| Diastolic BP (mmHg)* | 93.1 ± 7.8 | 90.9 ± 10.6 | 89.8 ± 8.3 | 87.3 ± 8.2 |
| HR (beats/min) | 364.2 ± 52.0 | 350.5 ± 83.0 | 357.8 ± 56.6 | 348.2 ± 45.7 |
| LV EF (%) | 75.8 ± 4.0 | 76.0 ± 3.0 | 76.2 ± 2.6 | 77.4 ± 4.2 |
| LV EDD (mm) | 7.08 ± 0.63 | 7.29 ± 0.52 | 6.90 ± 0.46 | 7.08 ± 0.66 |
| LV ESD (mm) | 4.26 ± 0.51 | 4.38 ± 0.40 | 3.93 ± 0.92 | 4.16 ± 0.59 |
| LV SWT (mm) | 1.14 ± 0.12 | 1.10 ± 0.20 | 1.14 ± 0.16 | 1.15 ± 0.14 |
| LV PWT (mm) | 1.28 ± 0.17 | 1.35 ± 0.15 | 1.29 ± 0.20 | 1.48 ± 0.17 |

Values area means ± SD. *Measured by noninvasive blood pressure. BP, blood pressure; HR, heart rate; LV, left ventricular; EF, ejection fraction; EDD, end diastolic dimension; ESD, end systolic dimension; SWT, diastolic posterior wall thickness; PWT, diastolic posterior wall thickness.
mm) and Low-fima (4.95 ± 0.52 mm) groups; however, LVESD in the DOX-only group was significantly increased compared with the fimasartan-treated groups (56 ± 0.6 mm, \( P = 0.009 \) by ANOVA). Furthermore, LVEF was preserved in the High-fima group (71.4% ± 6.3%) and slightly decreased in the Low-fima group (67.9% ± 5.3%) compared with the NC group (74.6% ± 3.7%).

Table 2. Echocardiographic data after 6 and 8 weeks of treatment

| Parameters          | Doxorubicin group          | Normal control (n = 8) | \( P \) value |
|---------------------|----------------------------|-----------------------|---------------|
|                     | Dox-only (n = 22)          | Low-fima (n = 22)     | High-fima (n = 19) |     |
| At 6 weeks          |                            |                       |               |
| HR (beats/min)      | 304.6 ± 52.0               | 334.5 ± 49.2          | 322.9 ± 84.3  | 352.7 ± 46.6 | 0.316 |
| LV EF (%)           | 61.7 ± 12.7                | 65.7 ± 14.9           | 73.2 ± 4.8*   | 73.6 ± 4.1  | 0.013* |
| LV EDD (mm)         | 7.48 ± 0.57                | 7.48 ± 0.63           | 7.46 ± 0.59   | 7.77 ± 0.92 | 0.993 |
| LV ESD (mm)         | 5.14 ± 0.56                | 4.93 ± 0.67           | 4.59 ± 0.65*  | 4.81 ± 0.71 | 0.032* |
| LV SWT (mm)         | 1.21 ± 0.20                | 1.11 ± 0.12           | 1.20 ± 0.13   | 1.30 ± 0.05 | 0.080 |
| LV PWT (mm)         | 1.29 ± 0.23                | 1.35 ± 0.21           | 1.21 ± 0.17   | 1.38 ± 0.20 | 0.130 |
| At 8 weeks          |                            |                       |               |
| HR (beats/min)      | 280.1 ± 40.2               | 329.8 ± 42.2*         | 346.0 ± 36.0* | 354.4 ± 53.6 | < 0.001* |
| LV EF (%)           | 54.6 ± 8.4                 | 67.9 ± 5.3*           | 71.4 ± 6.3*   | 74.6 ± 3.7  | < 0.001* |
| LV EDD (mm)         | 7.76 ± 0.41                | 7.42 ± 0.47*          | 7.30 ± 0.71   | 7.76 ± 0.53 | 0.077 |
| LV ESD (mm)         | 5.60 ± 0.60                | 4.95 ± 0.52*          | 4.94 ± 1.08*  | 4.76 ± 0.49 | 0.009* |
| LV SWT (mm)         | 1.12 ± 0.13                | 1.18 ± 0.19           | 1.17 ± 0.14   | 1.36 ± 0.16 | 0.577 |
| LV PWT (mm)         | 1.24 ± 0.14                | 1.24 ± 0.11           | 1.26 ± 0.13   | 1.50 ± 0.17 | 0.921 |

Values area means ± SD. *\( P \) value < 0.05 by ANOVA among doxorubicin injected group. HR, Heart rate; LV, left ventricular; EF, Ejection fraction; EDD, end diastolic dimension; ESD, end systolic dimension; SWT, diastolic posterior wall thickness; PWT, diastolic posterior wall thickness.
In contrast, LVEF was significantly decreased in the DOX-only group (54.6% ± 8.4%, \( P < 0.001 \) by ANOVA).

Only 55% of the DOX-only group survived to nine weeks before hemodynamic assessment. The Low-fima and High-fima groups had survival rates of 77% and 95%, respectively. All of the animals in the normal control group were alive at the end of the study (Fig. 3, \( P = 0.002 \) by log-rank test).

Diarrhea and abdominal distension associated with a large amount of ascites were common in the DOX-only group (\( n = 15 \) [68%] and \( n = 11 \) [50%], Table 3); however, these conditions did not occur in the High-fima group. A small number of animals (\( n = 6 \) [27%]) in the Low-fima group had diarrhea. Although none of the fimasartan-treated rats showed abdominal distension, a small amount of ascites was found in about a quarter of the rats treated with fimasartan when the abdominal walls were opened and the visceral space examined. Body weight at eight weeks was smallest in the DOX-only group. Severe anorexia, she-

Table 3. General conditions of study animals

| Conditions                  | Doxorubicin group | Normal control (n = 8) | \( P \) value |
|-----------------------------|-------------------|------------------------|--------------|
|                             | Dox-only          | Low-fima               | High-fima    |               |
| Body weight (8th week)*     | 279.3 ± 50.4      | 320.3 ± 40.7           | 317.2 ± 34.0 | < 0.001       |
| Eye discharge/conjunctival hemorrhage (No.) | 7 | 0 | 0 | 0 | < 0.001 |
| Diarrhea (No.)              | 15 | 6 | 0 | 0 | < 0.001 |
| Abdominal distension (No.)  | 11 | 0 | 0 | 0 | < 0.001 |
| Ascites (pathology) (No.)*  | 10 | 4 | 4 | 0 | < 0.001 |

*Evaluation for body weight and ascites was performed at the end of the study, therefore number of evaluated animals is as follows: Dox-only, \( n = 12 \); Low-fima, \( n = 19 \); High-fima, \( n = 19 \); normal control, \( n = 8 \).

Fig. 3. Survival curves and general features of study animals. Eight-week survival rate of the High-fima group is greater (100%) than that of Low-fima (75%) and DOX-only groups (50%, \( P < 0.05 \)).

Fig. 4. General feature of treated animals. (A) Rats in Dox-only group show severe shedding and ascites. (B) In contrast, rats in the High-fima group show no shedding or ascites.
dding, and eye discharge with conjunctival hemorrhage were also common in the DOX-only group. In contrast, rats in the High-fima group showed less anorexia and no shedding, eye discharge, or ascites (Table 3, Fig. 4).

**Table 4. Hemodynamic result at 9 weeks**

| Parameters                  | Doxorubicin group | Normal control | P value |
|-----------------------------|-------------------|----------------|---------|
|                             | Dox-only (n = 10) | Low-fima (n = 15) | High-fima (n = 13) | Normal control (n = 8) |         |
| Heart rate (beat/min)       | 237.5 ± 37.5      | 267.5 ± 30.9    | 266.9 ± 29.7      | 286.3 ± 63.5            | 0.057   |
| LV EDP (mmHg)               | 9.2 ± 3.5         | 9.0 ± 2.5       | 8.9 ± 3.3         | 9.0 ± 2.5               | 0.983   |
| +dP/dt                      | 3,425.3 ± 947.1   | 4,241.1 ± 888.4 | 5,931.6 ± 1,354.2 | 6,146.6 ± 1,439.0       | < 0.001*|
| -dP/dt                      | 3,121.9 ± 1,127.5 | 3,502.1 ± 1,088.1 | 5,410.3 ± 1,338.2 | 5,406.1 ± 1,074.6       | < 0.001*|
| Ees                         | 0.27 ± 0.18       | 0.25 ± 0.23     | 0.35 ± 0.23       | 0.31 ± 0.23             | 0.534   |
| Slope –EDPVR                | 0.03 ± 0.02       | 0.02 ± 0.01     | 0.03 ± 0.04       | 0.02 ± 0.01             | 0.609   |
| Emax                        | 0.89 ± 0.41       | 1.01 ± 1.67     | 0.99 ± 5.494      | 1.96 ± 2.57             | 0.210   |
| PRSW                        | 44.0 ± 14.5       | 52.3 ± 24.8     | 53.8 ± 50.6       | 57.1 ± 25.7             | 0.609   |
| dP/dt-EDV                   | 11.2 ± 9.5        | 12.3 ± 12.9     | 26.9 ± 21.5       | 28.9 ± 17.3             | 0.042*  |

*P value < 0.05 by ANOVA among doxorubicin injected group; †P value < 0.05 by post poc analysis compared to Dox-only group; ‡P value < 0.05 by post poc analysis compared to low-fima group. LV, left ventricular; ESV, end systolic volume; EDV, end-diastolic volume; τ, tau; Ees, end-systolic pressure-volume relation; Emax, maximum elastance; EDPVR, end-diastolic pressure volume relation; PRSW, preload recruitable stroke work.

**Fig. 5.** Left ventricular pressure-volume loop by microminiaturized press-volume catheterization. End-systolic pressure volume relation (ESPVR) slopes was significantly decreased in DOX-only and Low-fima groups, whereas slope values was similar to normal control in the High-fima group.
Hemodynamic data acquired using a micro-conductance catheter are summarized in Table 4 and Fig. 5. The absolute values of positive and negative dP/dt were highest in the High-fima group (5,931 ± 1,354 mmHg/sec and -5,410 ± 1,338 mmHg/sec) compared with the Low-fima (4,241 ± 888 mmHg/sec and -3,502 ± 1,088 mmHg/sec) and DOX-only groups (3,425 ± 947 mmHg/sec and -3,121 ± 1,127 mmHg/sec, \( P < 0.001 \) by ANOVA, respectively). However, other parameters such as Ea, Ees, Emax, and PRSW did not show statistically significant differences between the groups. dP/dt-EDV was significantly higher in the High-fima group, with similar values to normal controls. The end-systolic pressure volume relation (ESPVR) slopes were significantly decreased in the DOX-only and Low-fima groups, whereas slope values were similar to normal control in the High-fima group (Fig. 5).

Western blot analysis showed that pERK protein levels were decreased in the DOX-only group and increased in the High-fima group compared with the normal control group (Fig. 6A). In addition, pAKT protein levels were decreased both in the DOX-only group and in the High-fima group (Fig. 6B). There was a remarkable increase in pERK in the High-fima group compared with the DOX-only group (Fig. 6C). The expression of pAKT was significantly decreased compared to the normal control group and was decreased in the High-fima group without statistical significance (Fig. 6D). These findings suggest that fimasartan may activate cell survival signaling under Doxorubicin-induced cardiotoxicity.

**DISCUSSION**

In this study, a new ARB, fimasartan, prevented progressive DOX-induced cardiac dysfunction in a rat model of DOX-induced cardiomyopathy when administrated during DOX treatment. In addition this ARB also attenuated the systemic toxicity of DOX and improved the survival of rats in a dose-dependent manner.

Treatment for DOX-induced cardiomyopathy has been studied with respect to prevention or treatment after development of cardiomyopathy. The delayed occurrence of cardiomyopathy, even after as long as ten years (7), suggests that initial cardiac injury by DOX lasts for years, resulting in progressive irreversible damage to the myocardium. Therefore, pharmacological therapy for prevention should be initiated before the administration of DOX and continued for a long period of time, even after discontinuation of chemotherapy. The mechanism of DOX-induced cardiomyopathy is the production of free radicals and a decrease in endogenous antioxidant enzymes, which results in tissue-specific mitochondrial DNA damage induced by oxidative stress (7, 8). Therefore, antioxidant drugs are expected to be a possible preventive method for minimizing the toxic effects of DOX. Several pharmaceutical agents acting on oxidative stress have been evaluated in preclinical studies, and a few clinical trials have shown success (9, 10). However, the effect was limited and a risk of other adverse events such as secondary malignancy was reported.
The therapeutic effects of the long-term use of beta blockers, angiotensin converting enzyme inhibitor, or ARB have been established in patients with systolic heart failure in many clinical trials (11-13), and these drugs are expected to have a similar effect on heart failure from other causes. Carvedilol (14) and enalapril (15) were tested for the treatment of DOX-induced cardiomyopathy in preclinical and clinical studies with a small number of patients. In our data, high dose of fimasartan showed the superior effect on survival and hemodynamics than low dose of fimasartan. In previous clinical studies with ARB in heart failure or renal failure, dose dependent manner was observed (16, 17). It can be class-effect of ARB but further clinical study is needed in fimasartan.

The renin-angiotensin system plays a crucial role in the cardiovascular system, and angiotensin II is closely related to cardiac injury and the progression of ventricular remodeling in heart failure. Angiotensin II type 1 (AT1) receptor is especially associated with cellular proliferation, vasoconstriction, and sympathetic activation. The blockage of AT1 receptor with ARB has been reported to modulate neurohormonal activation and have antioxidative effects. Moreover, DOX-induced cardiomyopathy is not observed in AT1 receptor knock-out mice (18). Thus, AT1 receptor may play a role in the progression of DOX-induced cardiomyopathy. Several preclinical studies with ARB (19-21) showed the protective or therapeutic effects of ARB in a DOX-induced cardiomyopathy model via anti-inflammatory processes or a decrease in oxidative stress.

Fimasartan (BR-A-657; BR-A-657-K; Kanarb®) is a new angiotensin II receptor antagonist with high selectivity for the AT1 receptor subtype. Fimasartan shows superior inhibitory activity in the contraction of isolated rabbit thoracic aorta compared with other ARBs such as losartan and candesartan (22) and showed protective effect in acute myocardial infarction model in a recent study (23). In clinical trials with hypertensive patients, fimasartan shows non-inferiority to losartan for blood pressure control (22). Fimasartan has not previously been studied for the treatment of heart failure; however, it is expected to have an ARB class effect on heart failure, and its efficacy may be greater than expected because of its high affinity for AT1 receptor compared with other ARBs in preclinical studies.

In our study, the systemic toxicity of DOX was dramatically decreased by fimasartan treatment. The decreased toxicity may have been mediated by the ERK pathway, which is associated with cell survival, via an induction of ERK phosphorylation by high-dose fimasartan treatment. Another signaling pathway associated with cell survival, the AKT phosphorylation pathway, was not affected by fimasartan treatment. Damaged myocyte increase angiotensin II secretion and it is activating JAK-STAT pathway. Activated STAT signal pathway was negatively regulated MAPK signal. It could increase myocyte death. Thus DOX induce myocyte damage was significantly protected by fimasartan induce ERK signal cascade activation (24-28).

Potential cardiotoxicity by chemotherapeutic agents may last for years, resulting in insidious onset of overt cardiomyopathy after years of latency (29). Therefore, pharmacological therapy for prevention should be initiated at the time of DOX administration and be continued for a long period, even after the discontinuation of the chemotherapy. For this purpose, preventive agents should have long-term safety, tolerability, and low cost. Moreover, preventive medication should not alter the anti-tumor effects of DOX.

In this regard, ARBs are valuable pharmacological agents that can be used to prevent DOX-induced cardiomyopathy. The safety of ARBs has been well-studied in many clinical trials. Apart from other antihypertensive medications, incremental doses of ARBs decrease blood pressure, but rarely induce an abnormal reduction in blood pressure (11). In many clinical trials evaluating ARBs in hypertensive or heart failure patients, the adverse effects of ARBs were found to be minimal (11, 14, 22). The daily cost of ARBs can be managed by most patients when compared with the cost of chemotherapy and the fatal events that may occur when patients develop heart failure.

Our study showed that fimasartan had a strong preventive effect on DOX-induced cardiomyopathy. Moreover, fimasartan improved survival rates and systemic toxicity. These findings suggest that fimasartan may be a possible candidate to reduce adverse reactions during DOX-based chemotherapy such as cardiac and other systemic toxicity.

Our study did not evaluate the anti-tumor effects of fimasartan. In a previous study, AT1 receptor was shown to be associated with cellular proliferation; thus, ARBs have been reported to have anti-proliferative activity and anti-tumor effects (30). Therefore, the possibility of fimasartan treatment altering the anti-tumor effects of DOX is very low. The dosage of fimasartan used in this study was high in order to decrease the blood pressure of the study animals; therefore, this could be a possible limiting factor in clinical use. However, most ARBs have shown tolerable blood pressure reduction in clinical trials of patients with heart failure (11, 14).

In conclusion, a new ARB, fimasartan, when administrated during DOX treatment, prevented progressive DOX-induced cardiac dysfunction in a rat model of DOX-induced cardiomyopathy. In addition, fimasartan also attenuated the systemic toxicity of DOX and improved rat survival in a dose-dependent manner. These data demonstrate the possibility of fimasartan as a treatment option to prevent DOX-induced cardiac dysfunction and heart failure. For that reason, randomized clinical trials with fimasartan are warranted in the near future.

DISCLOSURE

The authors have no potential conflicts of interest to declare in
relation to this article.

**AUTHOR CONTRIBUTIONS**

Conceived and designed the study: Chang SA, Lim BK, Jeon ES. Data collection: Chang SA, Lee YJ, Hong MK, Lim BK. Analyzed the data: Chang SA, Lim BK, Choi JO. Statistical analysis: Chang SAS, Lim BK. Manuscript preparation: Chang SA, Lim BK, Choi JO, Jeon ES. Manuscript approval: all authors.

**ORCID**

Sung-A Chang  http://orcid.org/0000-0001-5124-605X
Eun-Seok Jeon  http://orcid.org/0000-0002-9946-5611

**REFERENCES**

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 906-5.
2. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.
3. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.
4. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy–risk factors. Cancer 1977; 38: 3937-402.
5. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiography in the current era. J Nucl Cardiol 2003; 10: 132-9.
6. Georgakopoulos D, Mitzner WA, Byrne BJ, Millar HD, Hare JM, Kass DA. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol 1998; 274: H1416-22.
7. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000; 207: 77-86.
8. Lebrecht D, Kokkori A, Ketelsken UP, Setzer B, Walker UA. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol 2005; 207: 436-44.
9. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-53.
10. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, et al. Protective effect of the bisperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52.
11. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
12. McMurray JJ, Osterreicher J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
13. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30: 27-34.
14. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48: 2258-62.
15. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-81.
16. Spjolje AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chatrurvedi N, DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385-93.
17. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegelger GA, Malbecq W, Smith RD, Guptha S, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840-8.
18. Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, Yamamoto R, Sugaya T, Komuro I. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002; 25: 357-603.
19. Soga M, Kamal FA, Watanabe K, Ma M, Palaniyandi S, Prakash P, Veeraveedu P, Mitto S, Kunisaki M, Tachikawa H, et al. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol 2006; 110: 378-85.
20. Ibrahim MA, Ashour OM, Ibrahim YE, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009; 60: 373-81.
21. Arozal W, Watanabe K, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Suzuki K, Kodama M, Aizawa Y. Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. J Pharm Pharmacol 2010; 62: 1776-83.
22. Kim JH, Lee JH, Paik SH, Kim JH, Chi YH. Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res 2012; 35: 1123-6.
23. Sim DS, Jeong MH, Song HC, Kim J, Chong A, Bom HS, Jeong IS, Oh SG, Kim JM, Park DS, et al. Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction. J Korean Med Sci 2010; 25: 307-16.
24. Omura T, Yoshiyama M, Ishikura F, Kobayashi K, Takeuchi K, Keppu S, Yoshikawa I. Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. J Mol Cell Cardiol 2001; 33: 307-16.
25. Inamura K, Matsuzaki Y, Uematsu N, Honda A, Tanaka N, Uchida K. Protective effect of the bispi.
26. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Messing RO, Bolli R. Role of the protein kinase C-epsilon-Raf-1-MEK-1-2/p144/42 MAPK signaling...
cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. Circulation 2005; 112: 1971-8.

27. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006; 71: 684-94.

28. Lu Y, Zhou J, Xu C, Lin H, Xiao J, Wang Z, Yang B. JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem 2008; 21: 305-14.

29. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 2629-36.

30. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003; 2: 1139-47.